Investigating retinal damage in COVID-19 patients using non-invasive imaging
COVID-19 Patient Cohort: Retinal Damage in Non-invasive Retinal Imaging (OCTA)
This study is testing if COVID-19 can cause damage to the eyes by using special imaging techniques on patients with different levels of illness.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Intercommunal Creteil Academic / other |
| Locations | 1 site (Créteil, IDF) |
| Trial ID | NCT04881253 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect non-invasive retinal imaging data, specifically using optical coherence tomography (OCT) and OCT angiography (OCTA), to assess the incidence and impact of retinal damage in patients with COVID-19. It includes three groups of participants: those hospitalized for COVID-19, newly diagnosed patients, and those with mild symptoms who did not require hospitalization. An ophthalmologic assessment will be conducted at inclusion, which includes visual acuity tests and various imaging techniques to detect potential retinal lesions. The study seeks to correlate clinical parameters with retinal vascular damage to enhance understanding of the disease's pathophysiology.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with COVID-19.
Not a fit: Patients who do not have a confirmed diagnosis of COVID-19 or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the retinal complications associated with COVID-19, potentially leading to better management and treatment strategies for affected patients.
How similar studies have performed: While this study focuses on a specific aspect of COVID-19, similar studies investigating retinal damage in other conditions have shown promising results, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * Diagnosis of COVID-19 proven on RT-PCR, antigenic test or chest CT scan * Affiliation to the general social security system * A consent signed by the patient Exclusion Criteria: - Refusal of patient participation
Where this trial is running
Créteil, IDF
- Centre Hospitalier Intercommunal de Créteil — Créteil, Idf, France (Recruiting)
Study contacts
- Study coordinator: Camille JUNG, MD
- Email: camille.jung@chicreteil.fr
- Phone: 01 45 17 50 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.